Nasdaq GlobeNewswire

Standard Lithium Provides Processing and Pilot Plant Update

Del

VANCOUVER, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to provide an update regarding the Company’s rapid progress in developing and building a large-scale Pilot Plant for deployment at the Arkansas project site.  The Company and its Scientific Advisory Team have been developing, testing and optimising proprietary lithium extraction and crystallisation technologies on Smackover brines for over a year, and are now at the stage where the process flowsheet is sufficiently tested and proven to allow procurement and fabrication to commence on the full-scale Pilot Plant.

A lithium extraction Mini-Pilot Plant has been operated continuously for long durations, and has demonstrated that lithium can be selectively extracted from raw Smackover brine (i.e. with no pre-treatment other than pH adjustment); can be converted into a concentrated and substantially purified (compared to the feed brine) lithium chloride solution; that the lithium-loaded sorbent material can be continuously regenerated and recycled to the extraction stage; and that overall lithium extraction efficiencies of over 90% can be achieved.  Completion of this work has allowed design of the large-scale lithium extraction Pilot Plant to be sufficiently completed, such that procurement of long lead-time equipment has commenced.  The procurement and fabrication of the lithium extraction Pilot Plant is being performed by Zeton Inc. at their design and fabrication facility in Burlington, Ontario.  Once fabrication of the modular Pilot Plant is complete, it will be shipped to the Project site in southern Arkansas for installation, commissioning and operation.  Initial site investigation and civil/mechanical engineering design work have commenced at the Project site, and it is expected that all site preparation and brine/utility interconnections will be completed well in advance of deployment of the Pilot Plant modules to the Project site.

In addition, the Company has been performing testwork to selectively crystallise ‘battery-grade’ lithium carbonate directly from the concentrated lithium chloride solutions produced by the Company’s proprietary lithium extraction technology.  This testwork has been successful in making high purity lithium carbonate material (>99.5% purity), and as previously announced (see Standard Lithium news release 06th June 2018), the Company and its technology partners are currently fabricating a Pilot scale crystallisation plant.  This first Pilot scale plant will be capable of running continuously, and will serve as proof-of-concept that Standard Lithium’s proprietary crystallisation technology can be used in place of existing OEM crystallisation technologies.  Should initial testing be successful, then a larger Pilot/Demo scale crystalliser will be constructed for deployment at the Project site.

Dr. Andy Robinson, President and COO of Standard Lithium commented, “Our Scientific Advisory Team and technology partners have been working tirelessly over the past 12 months to develop modern, efficient and scaleable technology solutions appropriate for deployment at our Project site in Arkansas.  We’re very excited that we’re now at the stage where procurement and construction of the full-scale Pilot equipment has commenced, and all project activities are aligned towards deploying the full-scale modular Pilot plant in the first part of 2019.  Standard Lithium has some significant milestones ahead of us in the next two quarters, and we look forward to sharing more details on our projects and proprietary process technologies as we issue technical reports over the coming months.

Quality Assurance
Dr. Ron Molnar, Professional Metallurgical Engineer (Ontario P.E.# 100111288) and Ross Lewis, Professional Engineer (APEGBC#116613), are qualified persons as defined by NI 43-101, and have reviewed and approved the relevant scientific and technical information that forms the basis for this news release.  Dr. Molnar and Mr. Lewis are independent of the Company.

About Standard Lithium Ltd.
The Company’s flagship project is located in southern Arkansas, where it is engaged in the testing and proving of the commercial viability of lithium extraction from over 150,000 acres of permitted brine operations utilising the Company’s proprietary selective extraction technology.  The Company is also pursuing the resource development of over 30,000 acres of separate brine leases located in southwestern Arkansas and approximately 45,000 acres of mineral leases located in the Mojave Desert in San Bernardino County, California.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

For further information, contact Anthony Alvaro at (604) 240 4793

On behalf of the Board,

Standard Lithium Ltd.
Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information.  These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information.  Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties.  Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

 

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08Pressemelding

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07Pressemelding

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol

Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44Pressemelding

SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo

Anomali Announces Major Expansion of Threat Platform Partner Ecosystem20.9.2018 16:00Pressemelding

New Developer SDKs enable partners to integrate solutions with Anomali Threat Platform NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the expansion of the partner ecosystem with the launch of a suite of partner developer resources. The new tools enable easier and faster integration with the Anomali Threat Platform and APP Store, allowing clients immediate access to partner content, integrations and analytics. The partner program expansion includes the launch of a suite of software development kits (SDKs). The SDKs address three critical integration areas: Threat Intelligence Feeds SDK: integrate proprietary threat intelligence feeds and make these accessible via the APP Store Integration SDK: integrate threat intelligence from the Anomali Threat Platform into third party products and solutions Enrichment SDK: integrate 3rd party threat analysis and data enrichments into the Anomali Threat Platform “Organizations need a com

Anomali Launches Comprehensive Threat Platform to Detect and Respond to Cyber Attacks20.9.2018 16:00Pressemelding

New Anomali Threat Platform delivers complete threat detection, analysis and response NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the launch of the Anomali Threat Platform, a comprehensive threat detection and response suite. The Anomali Threat Platform represents the culmination of five years of ongoing innovation to provide organizations a unified solution to identify cyberthreats, understand the adversary, and automate response. The Anomali Threat Platform is comprised of five core capabilities, each addressing a specific need for threat mitigation, and all working together to deliver a complete security solution. Intelligence: collection, optimization and enrichment of threat intelligence Investigation: understand cyber threats with comprehensive analyst workbench Detection: proactive detection of active, serious threats targeting client networks Automation: eliminate manual processes and streamline investigation an

Taconic Biosciences Becomes the First Animal Model Provider on Federal General Services Administration20.9.2018 15:40Pressemelding

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory products and equipment to federal, state, and local governments. Most notably, GSS has direct procurement relationships with the federal General Services Administration (GSA). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and also the only provider with a channel to the GSA. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable res

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom